Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07583745 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of EPN-701 for the Treatment of Calciphylaxis

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jun 30, 2030 → Sep 30, 2030
See other at-risk trials from Sagar U. Nigwekar, MD, MMSc

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2026 to Oct 1, 2026
    • Primary and study completion pushed from Jun 30, 2030 to Sep 30, 2030
    v3
  2. Collaborators expanded, about 3 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Calciphylaxis is a rare but serious condition that leads to painful skin lesions. At present, there is no approved treatment for calciphylaxis. This research study is planned to examine the potential benefits of a new treatment (EPN-701) in patients with calciphylaxis. The present early clinical study will also evaluate the pharmacology of EPN-701 and whether it can be safely used in patients with calciphylaxis. Findings will inform the planning of a future definitive study to establish EPN-701 as an approved treatment for calciphylaxis.
Trial Details
NCT Number NCT07583745
Lead Sponsor Sagar U. Nigwekar, MD, MMSc
Collaborators: Epizon Pharma, Inc.
Conditions
(from sponsor)		 Calciphylaxis
Related terms Calciphylaxis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov